Meningococcal Vaccine Market to Reach $4,192.6 Million, Grow At a CAGR of 9.5% From 2022 to 2026

The major factors that contribute to the growth of the meningococcal conjugate vaccine market include increasing prevalence of diseases caused by microorganisms such as Neisseria meningitides, improving healthcare infrastructure, development of quality vaccines at an affordable price, and growing awareness about meningococcal vaccination & associated immunization. However, high costs, adverse effects of vaccines, and stringent government regulations hamper the growth of the global meningococcal conjugate vaccine market. Development of combination vaccines and large numbers of mergers & acquisition strategies among key vendors are expected to propel the growth of the market in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/330

The global meningococcal vaccine market size was valued at $1,935.5 million in 2018, and is projected to reach $4,192.6 million by 2026, registering a CAGR of 9.5% from 2019 to 2026.

Increase in outbreaks of meningococcal disease, surge in immunization programs across the globe, and rise in research and development for vaccine technology propel the growth of the global meningococcal vaccine market. However, longer timelines required for vaccine production and high cost associated with the development of vaccines impede the market growth. On the other hand, rise in healthcare spending, increase in research and development for meningococcal vaccines, and growing opportunities in the emerging markets offer lucrative opportunities to the market players.

Rise in outbreaks of meningococcal disease, increase in immunization programs across the world, and surge in research and development for vaccine technology drive the global meningococcal vaccine market. However, long duration required for vaccine production and high cost of vaccine development hinder the market growth. On the other hand, increase in healthcare expenditure and untapped potential in emerging economies create new opportunities in the coming years.

Covid-19 scenario

Due to lockdown, immunization programs will come to a halt and program schedules will be changed in various countries.

Research and development activities for vaccine technology will be limited, as researchers need to stay at home during the lockdown.

Meningococcal vaccine is used as a placebo effect in the Covid-19 vaccine trial conducted at the University of Oxford.

Based on region, North America accounted for the highest share, holding nearly half of the total share in 2018, and is estimated to maintain its dominant share during the forecast period. On the other hand, the Asia-Pacific region is also anticipated to manifest the fastest CAGR of 14.7% from 2019 to 2026. The market also analyses regions including Europe, North America, and LAMEA.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/330

North America to maintain its dominance throughout the forecast period

Based on region, North America accounted for the largest market share in terms of revenue in 2018, holding nearly half of the global meningococcal vaccine market, and is estimated to maintain its lead position throughout the forecast period. This is due to surge in prevalence of meningitis disease and ease in availability of meningococcal vaccine products for treatment of the disease. However, Asia-Pacific is expected to portray the largest CAGR of 14.7% from 2019 to 2026, owing to surge in outbreaks of meningococcal diseases and widespread availability of products.

Leading market players

Bio-Manguinhos
Bio-Med Pvt. Limited
Chongqing Zhifei Biological Products Co., Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Incepta Pharmaceuticals Ltd.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
Walvax Biotechnology Co., Ltd.

We also Offers Regional and Country Reports-

Japan Meningococcal Vaccine Market
South Korea Meningococcal Vaccine Market
Singapore Meningococcal Vaccine Market
China Meningococcal Vaccine Market
Indonesia Meningococcal Vaccine Market
Australia Meningococcal Vaccine Market
Taiwan Meningococcal Vaccine Market

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

Leave a comment

Your email address will not be published. Required fields are marked *